Recent performance and business snapshot

AMN Healthcare Services (AMN) has drawn attention after a sharp move in the stock, with recent returns of 4.8% over the past day, roughly 47% over the past week, and about 66% over the past month.

Over the past 3 months the stock is up about 90%, while the year to date gain is about 104% and the 1 year total return is about 42%. These moves come as the company reports annual revenue of US$3,419.3m and a net loss of US$32.4m, alongside annual revenue growth that declined 12.6% and net income growth that improved 16.2%.

The recent surge in AMN's share price, capped by a 1 month share price return of 66.1% and a 1 year total shareholder return of 41.8%, comes against a much weaker 3 and 5 year total shareholder return. This suggests momentum has picked up only recently as investors reassess both growth prospects and risk after the latest annual results.

If AMN's move has you rethinking opportunities in healthcare-related technology, it could be worth scanning a wider set of companies using our healthcare focused 33 healthcare AI stocks

With AMN trading at US$30.87 against an analyst price target of US$26.86, but showing an estimated 50% intrinsic discount, should you view the current level as a fresh opportunity or as a sign that markets already expect stronger growth?

Most Popular Narrative: 39% Overvalued

AMN closed at $30.87 against a narrative fair value of $22.21, so the most followed view sees the recent price move running ahead of fundamentals.

The normalization of contingent labor, combined with a growing preference among healthcare systems for flexible staffing, shown by a rebound in traveler extension rates and continued client interest in managed service provider (MSP) models, suggests a persistent structural shift that should bolster AMN's future fill rates and revenue pipeline.

Want to understand why a company with declining revenue expectations can still justify a premium to older targets? The narrative leans heavily on margin repair, a reset earnings base, and a future profit multiple that sits well below broader healthcare peers. Curious which mix of flat revenues, rising profitability and share count assumptions underpin that fair value path and analyst target range? Read on to see how those moving parts fit together.

Result: Fair Value of $22.21 (OVERVALUED)

However, you still need to weigh risks such as hospitals shifting more spending to permanent staff and the margin pressure flagged around wage inflation and pricing.

Another View: Cash Flows Point the Other Way

While the narrative fair value of $22.21 suggests AMN is about 39% overvalued, our DCF model points in the opposite direction, indicating the stock is trading about 50% below an estimated future cash flow value of $61.96. Which framework do you trust more when the signals clash this sharply?

Next Steps

The mix of bullish and cautious signals can feel conflicting, so it helps to move quickly and review the data yourself before sentiment shifts. To see exactly which potential upsides are getting investors excited right now, check out the 3 key rewards

Looking for more investment ideas?

If AMN has sharpened your focus on healthcare and valuation, do not stop here, broaden your watchlist with other stocks that fit what you are really looking for.

• Zero in on quality at a discount by checking companies that screen well for both fundamentals and price using the 46 high quality undervalued stocks
• Strengthen your income stream by spotting companies with higher yields and resilient payouts through the 14 dividend fortresses
• Sleep easier by focusing on companies with balance sheets designed to handle shocks, highlighted in the 68 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.